- Home
- NVNI vs ATNM Comparison
NVNI vs ATNM Comparison
Compare NVNI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- ATNM
- Stock Information
- Founded
- NVNI 2019
- ATNM 2000
- Country
- NVNI Brazil
- ATNM United States
- Employees
- NVNI N/A
- ATNM N/A
- Industry
- NVNI
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- ATNM Health Care
- Exchange
- NVNI Nasdaq
- ATNM Nasdaq
- Market Cap
- NVNI 57.2M
- ATNM 50.2M
- IPO Year
- NVNI N/A
- ATNM N/A
- Fundamental
- Price
- NVNI $3.23
- ATNM $1.27
- Analyst Decision
- NVNI
- ATNM Strong Buy
- Analyst Count
- NVNI 0
- ATNM 2
- Target Price
- NVNI N/A
- ATNM $4.50
- AVG Volume (30 Days)
- NVNI 274.9K
- ATNM 295.8K
- Earning Date
- NVNI 09-30-2025
- ATNM 11-14-2025
- Dividend Yield
- NVNI N/A
- ATNM N/A
- EPS Growth
- NVNI N/A
- ATNM N/A
- EPS
- NVNI N/A
- ATNM N/A
- Revenue
- NVNI $31,250,627.00
- ATNM N/A
- Revenue This Year
- NVNI $12.05
- ATNM N/A
- Revenue Next Year
- NVNI $15.02
- ATNM N/A
- P/E Ratio
- NVNI N/A
- ATNM N/A
- Revenue Growth
- NVNI 1491.58
- ATNM N/A
- 52 Week Low
- NVNI $1.44
- ATNM $1.03
- 52 Week High
- NVNI $121.90
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- NVNI 51.43
- ATNM 33.84
- Support Level
- NVNI $3.17
- ATNM $1.39
- Resistance Level
- NVNI $3.47
- ATNM $1.40
- Average True Range (ATR)
- NVNI 0.32
- ATNM 0.09
- MACD
- NVNI -0.17
- ATNM -0.02
- Stochastic Oscillator
- NVNI 13.76
- ATNM 6.86
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.